Keep Potential Eye Risks With GLP-1 Agonists in Sight

August 2025

You’ll see concerns about eye problems with GLP-1 agonists (semaglutide, etc)...due to recent data.

Most GLP-1 agonist labels already warn about diabetic retinopathy.

Now a new study links GLP-1 agonists to neovascular (or “wet”) age-related macular degeneration (nAMD)...where abnormal blood vessels grow under the retina and leak fluid, which can lead to central vision loss.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote